Corbus Pharma To Report Phase 1a Results Of CRB-913 In Obesity Today

Corbus Pharmaceuticals will present Phase 1a results for CRB‑913, an oral second‑generation CB1 inverse agonist engineered to be highly peripherally restricted to reduce central nervous system exposure, in a webcast on Dec. 11, 2025; the SAD/MAD study in healthy volunteers will inform dose selection for a planned Phase 1b in obese, non‑diabetic patients expected before year‑end. Preclinical data show CRB‑913 is ~15‑fold less brain‑penetrant than monlunabant and has ~50‑fold lower brain:plasma ratio than rimonabant, supporting a differentiated safety profile versus earlier CB1 agents withdrawn for neuropsychiatric events; the company reported $104m cash at Sept. 30 and, after a $73.8m November offering, expects runway into 2028—news that pushed premarket shares higher.

Analysis

Corbus Pharmaceuticals will present Phase 1a results for CRB-913, an oral, second-generation CB1 inverse agonist, in a webcast on December 11, 2025; the trial is a single ascending dose/multiple ascending dose (SAD/MAD) study in healthy volunteers and is intended to inform dose selection for a planned Phase 1b in obese, non-diabetic patients expected before year-end. CRB-913 is engineered to be highly peripherally restricted to minimize CNS exposure, addressing the class risk that led earlier CB1 agents to be discontinued for neuropsychiatric adverse events.

Preclinical data cited by the company show CRB-913 is approximately 15-fold less brain penetrant than monlunabant and has about a 50-fold lower brain:plasma ratio than rimonabant, which supports a differentiated safety hypothesis but remains preclinical and must be confirmed by human PK and safety readouts. Absent clear human evidence of peripheral restriction and an absence of CNS adverse events, safety concerns that sunk prior CB1 programs will remain the principal clinical risk.

Corbus reported $104 million in cash, cash equivalents and investments as of September 30, 2025, and completed a $73.8 million public offering in November that the company expects will extend runway into 2028, lowering near-term financing pressure. The stock has traded between $4.64 and $20.56 over the past year and was trading premarket at $11.82, up 15.20%, underscoring headline-driven volatility; the key near-term catalysts are the Phase 1a safety/PK data and the design and timing of the Phase 1b study.

Key Decisions for Investors

• Monitor the webcast closely for human PK and safety data—specifically confirmation of peripheral restriction and absence of CNS adverse events—as those readouts are the primary catalysts to justify increasing exposure
• Maintain a modest, staged position size given the binary nature of early clinical data and the translation risk from healthy volunteers to obese patients, adding only if Phase 1a demonstrates clear safety and dose-selection metrics
• Factor the extended cash runway into 2028 as reducing immediate dilution risk, but be prepared for high volatility around clinical milestones and reassess once Phase 1b design and timing are disclosed